AR109024A1 - USE OF SIGMA RECEIVER LIGANDS IN POST-HERPETIC PAIN - Google Patents

USE OF SIGMA RECEIVER LIGANDS IN POST-HERPETIC PAIN

Info

Publication number
AR109024A1
AR109024A1 ARP170101927A ARP170101927A AR109024A1 AR 109024 A1 AR109024 A1 AR 109024A1 AR P170101927 A ARP170101927 A AR P170101927A AR P170101927 A ARP170101927 A AR P170101927A AR 109024 A1 AR109024 A1 AR 109024A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
nr8r9
aromatic
halogen
Prior art date
Application number
ARP170101927A
Other languages
Spanish (es)
Inventor
Carlos Plata-Salaman
- Cebrecos-Prez Jess Ramn
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR109024A1 publication Critical patent/AR109024A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Compuesto de acuerdo con la fórmula general (1) o una sal, isómero, profármaco o solvato farmacéuticamente aceptable del mismo, para uso en la prevención y/o tratamiento del dolor post-herpético, donde R¹ se selecciona a partir del grupo constituido por hidrógeno, alquilo sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, alquenilo sustituido o sin sustituir, arilo sustituido o sin sustituir, arilalquilo sustituido o sin sustituir, heterociclilo no aromático sustituido o sin sustituir, heterociclilo aromático sustituido o sin sustituir, heterociclilalquilo sustituido o sin sustituir, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R² se selecciona entre el grupo que consiste en hidrógeno, alquilo sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, alquenilo sustituido o sin sustituir, arilo sustituido o sin sustituir, arilalquilo sustituido o sin sustituir, heterociclilo aromático o no aromático, sustituido o sin sustituir, heterociclilalquilo sustituido o sin sustituir, - COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹ y halógeno; R³ y R⁴ se seleccionan independientemente a partir del grupo constituido por hidrógeno, alquilo sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, alquenilo sustituido o sin sustituir, arilo sustituido o sin sustituir, arilalquilo sustituido o sin sustituir, heterociclilo aromático o no aromático, sustituido o sin sustituir, heterociclilalquilo sustituido o sin sustituir, -COR⁸, -C(O)OR⁸, -C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹, y halógeno, o juntos forman un sistema anular condensado sustituido opcionalmente; R⁵ y R⁶ se seleccionan independientemente a partir del grupo constituido por hidrógeno, alquilo sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, alquenilo sustituido o sin sustituir, arilo sustituido o sin sustituir, arilalquilo sustituido o sin sustituir, heterociclilo aromático o no aromático, sustituido o sin sustituir, heterociclilalquilo sustituido o sin sustituir, -COR⁸, -C(O)OR⁸, - C(O)NR⁸R⁹, -CH=NR⁸, -CN, -OR⁸, -OC(O)R⁸, -S(O)ₜ-R⁸, -NR⁸R⁹, -NR⁸C(O)R⁹, -NO₂, -N=CR⁸R⁹, y halógeno, o juntos forman, con el átomo de nitrógeno al cual se encuentran unidos, un grupo heterociclilo aromático o no aromático, sustituido o sin sustituir; n se selecciona entre 1, 2, 3, 4, 5, 6, 7 u 8; t es 1, 2 ó 3; R⁸ y R⁹ se seleccionan cada uno independientemente entre hidrógeno, alquilo sustituido o sin sustituir, cicloalquilo sustituido o sin sustituir, alquenilo sustituido o sin sustituir, arilo sustituido o sin sustituir, heterociclilo aromático o no aromático, sustituido o sin sustituir, alcoxi sustituido o sin sustituir, ariloxi sustituido o sin sustituir y halógeno.Claim 1: Compound according to the general formula (1) or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof, for use in the prevention and / or treatment of post-herpetic pain, where R¹ is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted aromatic heterocyclyl, heterocyclylalkyl substituted or unsubstituted, -COR⁸, -C (O) OR⁸, -C (O) NR⁸R⁹, -CH = NR⁸, -CN, -OR⁸, -OC (O) R⁸, -S (O) ₜ-R⁸, - NR⁸R⁹, -NR⁸C (O) R⁹, -NO₂, -N = CR⁸R⁹ and halogen; R² is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted substitute, substituted or unsubstituted heterocyclylalkyl, - COR⁸, -C (O) OR⁸, -C (O) NR⁸R⁹, -CH = NR⁸, -CN, -OR⁸, -OC (O) R⁸, -S (O) ₜ- R⁸, -NR⁸R⁹, -NR⁸C (O) R⁹, -NO₂, -N = CR⁸R⁹ and halogen; R³ and R⁴ are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted, substituted or unsubstituted heterocyclyl alkyl, -COR⁸, -C (O) OR⁸, -C (O) NR⁸R⁹, -CH = NR⁸, -CN, -OR⁸, -OC (O) R⁸, -S (O ) ₜ-R⁸, -NR⁸R⁹, -NR⁸C (O) R⁹, -NO₂, -N = CR⁸R⁹, and halogen, or together form an optionally substituted condensed ring system; R⁵ and R⁶ are independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted, substituted or unsubstituted heterocyclylalkyl, -COR⁸, -C (O) OR⁸, -C (O) NR⁸R⁹, -CH = NR⁸, -CN, -OR⁸, -OC (O) R⁸, -S (O ) ₜ-R⁸, -NR⁸R⁹, -NR⁸C (O) R⁹, -NO₂, -N = CR⁸R⁹, and halogen, or together form, with the nitrogen atom to which they are attached, an aromatic or non-aromatic heterocyclyl group, substituted or without replacing; n is selected from 1, 2, 3, 4, 5, 6, 7 or 8; t is 1, 2 or 3; R⁸ and R⁹ are each independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted, substituted or unsubstituted alkoxy substitute, substituted or unsubstituted aryloxy and halogen.

ARP170101927A 2016-07-12 2017-07-11 USE OF SIGMA RECEIVER LIGANDS IN POST-HERPETIC PAIN AR109024A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382331 2016-07-12

Publications (1)

Publication Number Publication Date
AR109024A1 true AR109024A1 (en) 2018-10-17

Family

ID=56418477

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101927A AR109024A1 (en) 2016-07-12 2017-07-11 USE OF SIGMA RECEIVER LIGANDS IN POST-HERPETIC PAIN

Country Status (4)

Country Link
AR (1) AR109024A1 (en)
ES (1) ES2701975R1 (en)
TW (1) TW201806601A (en)
WO (1) WO2018011169A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139061B2 (en) * 2004-08-27 2013-02-06 ラボラトリオス デル ドクトール エステベ エセ．ア． Sigma receptor inhibitor
PT2531177T (en) 2010-02-04 2016-08-17 Esteve Labor Dr 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and solvates
EP2460519A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
MA41177A (en) * 2014-12-15 2017-10-24 Esteve Labor Dr USE OF SIGMA RECEPTOR LIGANDS IN ARTHROSIS

Also Published As

Publication number Publication date
WO2018011169A1 (en) 2018-01-18
ES2701975A2 (en) 2019-02-26
ES2701975R1 (en) 2019-03-01
TW201806601A (en) 2018-03-01

Similar Documents

Publication Publication Date Title
AR104417A2 (en) TIADIAZOLIDINE COMPOUNDS, PROCEDURE FOR PREPARATION, PHARMACEUTICAL COMPOSITION THAT COMPOSES IT AND USES OF SUCH COMPOUNDS
AR119651A1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS TO TREAT HUNTINGTON'S DISEASE
AR096709A1 (en) LIGANDOS SIGMA FOR THE PREVENTION AND TREATMENT OF PAIN ASSOCIATED WITH INTERSTICIAL CISTITIS / VESICAL PAIN SYNDROME (CI / SDV)
AR084730A1 (en) NITROGEN HETEROCICLICAL LIGANDS OF SIGMA RECEPTORS USEFUL FOR THE TREATMENT OF BONE CANCER
AR108011A1 (en) ESTROGEN RECEIVING MODULATORS
AR086636A1 (en) SIGMA LINKS USEFUL TO TREAT AND / OR PREVENT THE PAIN ASSOCIATED WITH TYPE 2 DIABETES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR078609A1 (en) 8-ETIL-6- (ARIL) PIRIDO [2,3-D] PIRIMIDIN-7 (8H) -ONAS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEMS, SUCH AS DEPRESSION AND CANCERES OF OVARIO AND RENALES, AMONG OTHERS.
DOP2018000187A (en) DERIVATIVES OF PIRAZOLO [1,5-A] PIRAZIN-4-ILO
PE20180929A1 (en) NOVEL ANALOGS OF NUCLEOSIDES REPLACED IN THE BICYCLIC AROMATIC RING 6-6 FOR USE AS PRMT5 INHIBITORS
AR114044A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS IN THE CENTRAL NERVOUS SYSTEM
AR110405A1 (en) COMPOUNDS
AR107912A1 (en) RET INHIBITORS
AR101637A1 (en) COMBINATIONS OF GABAPENTINOIDS AND LIGANDS OF SIGMA RECEPTORS
AR106293A1 (en) FARNESOID X RECEIVER MODULATORS
AR104176A1 (en) IDO INHIBITORS (INDOLAMINE-2,3-DIOXYGENASE)
AR104884A1 (en) 4-HYDROXI-3- (HETEROARIL) PIRIDIN-2-ONA COMPOUNDS AS APJ AGONISTS
AR086632A1 (en) LIGANDOS SIGMA FOR THE PREVENTION AND / OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY
AR089143A1 (en) SUBSTITUTED TRIAZOLOPIRIDINS WITH INHIBITING ACTIVITY OF TTK
AR077876A1 (en) LIGANDOS OF THE SIGMA RECEIVER FOR THE PREVENTION OR TREATMENT OF PAIN INDUCED BY CHEMOTHERAPY
AR100021A1 (en) SIGMA AND AINE RECEIVER BINDING COMBINATIONS
CO6410301A2 (en) 1 ARIL -3- AMINOALCOXI-PIRAZOLES AS LIGANDOS SIGMA TO POTENTIATE THE ANALGESIC EFFECT OF THE OPIOIDES AND ATTACH THE DEPENDENCE OF THEM
AR112216A1 (en) DERIVATIVES OF AZAQUINOLINE
AR100808A1 (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
AR082441A1 (en) USE OF LIGANDOS SIGMA IN HYPERALGESIA INDUCED BY OPIOIDES
AR101638A1 (en) COMBINATIONS OF INHIBITORS OF SEROTONIN-NOREPINEFRINE (IRSN) RECRUITMENT AND SIGMA RECEIVER LIGANDS

Legal Events

Date Code Title Description
FB Suspension of granting procedure